964 related articles for article (PubMed ID: 15606381)
1. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial.
de Jager J; Kooy A; Schalkwijk C; van der Kolk J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
J Intern Med; 2014 Jan; 275(1):59-70. PubMed ID: 23981104
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals.
Stam F; Schalkwijk CG; van Guldener C; ter Wee PM; Stehouwer CD
Nephrol Dial Transplant; 2006 Mar; 21(3):677-82. PubMed ID: 16330467
[TBL] [Abstract][Full Text] [Related]
4. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
[TBL] [Abstract][Full Text] [Related]
5. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
Douek IF; Allen SE; Ewings P; Gale EA; Bingley PJ;
Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
7. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
8. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
9. Triglycerides as an early pathophysiological marker of endothelial dysfunction in nondiabetic women with a previous history of gestational diabetes.
Sokup A; Góralczyk B; Góralczyk K; Rość D
Acta Obstet Gynecol Scand; 2012 Feb; 91(2):182-8. PubMed ID: 21954994
[TBL] [Abstract][Full Text] [Related]
10. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
[TBL] [Abstract][Full Text] [Related]
11. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
12. Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training.
Ostergård T; Nyholm B; Hansen TK; Rasmussen LM; Ingerslev J; Sørensen KE; Bøtker HE; Saltin B; Schmitz O
Metabolism; 2006 Nov; 55(11):1508-15. PubMed ID: 17046554
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Sidhu JS; Cowan D; Kaski JC
Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
[TBL] [Abstract][Full Text] [Related]
15. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
[TBL] [Abstract][Full Text] [Related]
16. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia.
Spoelstra-de MA; Brouwer CB; Terheggen F; Bollen JM; Stehouwer CD; Smulders YM
Neth J Med; 2004; 62(7):246-53. PubMed ID: 15554600
[TBL] [Abstract][Full Text] [Related]
17. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
Nagi DK; Ali VM; Yudkin JS
Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
19. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus.
Carter AM; Bennett CE; Bostock JA; Grant PJ
Diabet Med; 2005 Sep; 22(9):1282-4. PubMed ID: 16108864
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of metformin in type 2 diabetes.
Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
Diabetes Obes Metab; 2007 May; 9(3):330-6. PubMed ID: 17391159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
